PATENTSCOPE will be unavailable a few hours for maintenance reason on Monday 03.02.2020 at 10:00 AM CET
Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (CN108701172) HIGH-THROUGHPUT IDENTIFICATION OF PATIENT-SPECIFIC NEOEPITOPES AS THERAPEUTIC TARGETS FOR CANCER IMMUNOTHERAPIES

Office : China
Application Number: 201780011208.5 Application Date: 10.02.2017
Publication Number: 108701172 Publication Date: 23.10.2018
Publication Kind : A
Prior PCT appl.: Application Number:PCTUS2017017549 ; Publication Number: Click to see the data
IPC:
G06F 19/18
C12Q 1/6886
G01N 33/569
G01N 33/574
A61K 35/17
A61K 39/00
A61K 39/395
A61K 47/50
A61K 48/00
A61P 35/00
G PHYSICS
06
COMPUTING; CALCULATING; COUNTING
F
ELECTRIC DIGITAL DATA PROCESSING
19
Digital computing or data processing equipment or methods, specially adapted for specific applications
10
Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
18
for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
[IPC code unknown for C12Q 1/6886]
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
569
for micro-organisms, e.g. protozoa, bacteria, viruses
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
574
for cancer
[IPC code unknown for A61K 35/17]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
[IPC code unknown for A61K 47/50]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
CPC:
G16B 20/00
A61K 35/17
A61K 39/00
A61K 39/0011
A61K 39/395
A61K 39/39558
A61K 45/06
A61K 47/6851
A61K 48/00
C12Q 1/6886
C12Q 2600/106
C12Q 2600/156
Applicants: NANTOMICS LLC
南托米克斯有限责任公司
NANT HOLDINGS IP LLC
河谷控股IP有限责任公司
Inventors: NGUYEN ANDREW
安德鲁·纽伦
SANBORN JOHN ZACHARY
约翰·扎卡里·桑伯恩
BENZ STEPHEN CHARLES
斯蒂芬·查尔斯·本茨
NIAZI KAYVAN
卡伊万·尼亚兹
RABIZADEH SHAHROOZ
沙赫鲁兹·拉比扎德
SOON-SHIONG PATRICK
派翠克·松吉翁
VASKE CHARLES JOSEPH
查尔斯·约瑟夫·瓦斯克
Agents: 北京柏杉松知识产权代理事务所(普通合伙) 11413
北京柏杉松知识产权代理事务所(普通合伙) 11413
Priority Data: 62/294,665 12.02.2016 US
Title: (EN) HIGH-THROUGHPUT IDENTIFICATION OF PATIENT-SPECIFIC NEOEPITOPES AS THERAPEUTIC TARGETS FOR CANCER IMMUNOTHERAPIES
(ZH) 高通量识别患者特异性新表位作为癌症免疫疗法的治疗靶点
Abstract: front page image
(EN) Systems and methods are presented that allow for selection of tumor neoepitopes that are filtered for various criteria. In particularly contemplated aspects, filtering includes a step in which the mutation leading to the neoepitope is ascertained as being located in a cancer driver gene.
(ZH) 提出了能够选择肿瘤新表位的系统和方法,所述肿瘤新表位针对各种标准进行过滤。在具体的预期方面,过滤包括其中确定导致新表位的突变为位于癌症驱动基因的步骤。
Also published as:
AU2017217877CA3014252SG11201806282XKR1020180091119IL261090EP3414692
US20190034582WO/2017/139694